In development: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Area of interest

Area of interest

Type

Type

Guidance programme 1 selected

Guidance programme

Showing 101 to 110 of 300

TitleTypeExpected publication date
Fordadistrogene movaparvovec for treating Duchenne muscular dystrophy [ID6133]Technology appraisal guidanceTBC
Ganaxolone for adjunctive treatment of epilepsy associated with tuberous sclerosis complex with CDKL5 deficiency disorder [TSID12126]Technology appraisal guidanceTBC
Garadacimab for preventing recurrent attacks of hereditary angioedema in people 12 years and over [ID6394]Technology appraisal guidance
Giroctocogene fitelparvovec for treating moderately severe to severe haemophilia A ID6312Technology appraisal guidanceTBC
Givinostat for treating Duchenne muscular dystrophy in people 6 years and over [ID6323]Technology appraisal guidance
Glofitamab with gemcitabine and oxaliplatin for treating relapsed or refractory diffuse B-cell lymphoma [ID6202]Technology appraisal guidanceTBC
Glycopyrronium bromide cream for treating severe primary axillary hyperhidrosis [ID6487]Technology appraisal guidance
Govorestat for treating classic galactosemia in people 2 to 65 years [TSID12071]Technology appraisal guidanceTBC
Guselkumab for previously treated moderately to severely active Crohn's disease ID6238Technology appraisal guidance
Guselkumab for treating moderately to severely active ulcerative colitis [ID6237]Technology appraisal guidance

Results per page

  1. 10
  2. 25
  3. 50
  4. All